酪氨酸激酶抑制剂对慢性髓细胞性白血病儿童生长发育影响的研究进展

Progress on the effects of tyrosine kinase inhibitors on the growth and development of children with chronic myelogenous leukemia

酪氨酸激酶抑制剂(tyrosine kinase inhibitor,TKI)的应用改变了儿童慢性髓细胞性白血病(chronic myeloid leukemia,CML)的治疗模式,显著改善了患儿预后。然而,长期使用TKI治疗CML患儿可能伴随的潜在不良反应值得关注,目前国内外均有研究发现应用TKI会使CML患儿的生长发育减速。该文对TKI导致CML患儿生长障碍的机制、临床研究结果、改善方法以及治疗过程中监测指标的研究进展进行综述。

The introduction of tyrosine kinase inhibitor(TKI)into the treatment of pediatric chronic myelogenous leukemia(CML)has led to treatment mode changes and significant improvements in prognosis.However,the potential adverse effects associated with long-term TKI therapy in pediatric CML patients merit close attention.Recent domestic and international studies have noted that TKI therapy may impede growth and development in children.This article reviews the research progress on the mechanism,clinical research findings,improvement methods,and monitoring indicators of growth disorder in children with CML caused by TKI.